Sobi's Aspaveli® Secures European Commission Approval for C3G Treatment Sobi has announced the European Commission's approval of Aspaveli® for treating C3 glomerulopathy in patients aged 12 and above. This marks a major milestone in addressing rare kidney diseases.

Sobi's Aspaveli® Secures European Commission Approval for C3G Treatment #Sweden #Stockholm #Sobi #Aspaveli #C3G

Sobi's Aspaveli® Advances Towards Approval for Rare Kidney Diseases in Europe Sobi's Aspaveli® (pegcetacoplan) has gained a positive opinion from the CHMP for treating C3G and IC-MPGN in Europe, a breakthrough for patients.

Sobi's Aspaveli® Advances Towards Approval for Rare Kidney Diseases in Europe #Sweden #Stockholm #Aspaveli #C3G #IC-MPGN

Sobi Announces Significant Changes in Partnership with Apellis for Aspaveli Royalties Sobi and Apellis Pharmaceuticals have revised their agreement concerning Aspaveli royalties, marking a transformative step in their collaboration.

Sobi Announces Significant Changes in Partnership with Apellis for Aspaveli Royalties #USA #Stockholm #Sobi #Aspaveli #Apellis

Sobi Announces Significant Restructuring of Royalty Agreement with Apellis for Aspaveli Sobi has restructured its existing royalty agreement with Apellis Pharmaceuticals, reducing its royalty payment obligations significantly, part of a strategic partnership.

Sobi Announces Significant Restructuring of Royalty Agreement with Apellis for Aspaveli #Sweden #Stockholm #Sobi #Aspaveli #Apellis

Sobi and Apellis Reveal Long-Term Benefits of Aspaveli® in Kidney Disease Study Sobi and Apellis present promising results from the Phase 3 study of Aspaveli® for rare kidney diseases, showing sustained efficacy over one year.

Sobi and Apellis Reveal Long-Term Benefits of Aspaveli® in Kidney Disease Study #Sweden #Stockholm #Sobi #Aspaveli #Apellis

EMA Validates Aspaveli® Application for Extended Use in Rare Kidney Disease Treatment The European Medicines Agency has validated an application for Aspaveli® to treat C3 glomerulopathy and IC-MPGN, rare kidney diseases without existing therapies.

EMA Validates Aspaveli® Application for Extended Use in Rare Kidney Disease Treatment #Sweden #Stockholm #Aspaveli #C3G #Apellis